Are Peptides Legal in South Dakota? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for South Dakota as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed South Dakota attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no South Dakota statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that South Dakota has scheduled or banned on its own. The South Dakota Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

South Dakota at a glance

State controlled-substances law: S.D. Codified Laws ch. 34-20B (Drugs and Substances Control); schedules in §§ 34-20B-11 to 34-20B-26; possession offence at SDCL § 22-42-5 (sdlegislature.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (SDCL § 34-20B-22(3) and § 34-20B-4.1) (sdlegislature.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's January 2024 newsletter told licensees that 503A and 503B pharmacies may compound shortage-list GLP-1s only if the active ingredient is not a salt or other form of the drug (semaglutide may only be compounded with semaglutide base), noted that most spas and wellness centres dispense non-FDA-approved compounded product, reported one South Dakota adverse event from a tenfold dosing error, and flagged counterfeit semaglutide reports (2024-01) (doh.sd.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. SDCL § 34-52-3 requires a proper provider-patient relationship via telehealth, with identity verification, consent, a diagnosis through acceptable medical practice including history and examination, and follow-up; § 34-52-5 requires an appropriate face-to-face examination using real-time audio and visual technology before diagnosis and treatment whenever an in-person encounter would otherwise be required. There is no in-person visit requirement for non-controlled drugs such as semaglutide, but a questionnaire-only model would not meet the statute. (sdlegislature.gov)
State-level enforcement, 2023 to 2026: None found
Last verified: 28 September 2026, confidence high

The federal rules that apply in South Dakota, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in South Dakota:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including South Dakota. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What South Dakota law adds

South Dakota's controlled-substances law (S.D. Codified Laws ch. 34-20B (Drugs and Substances Control); schedules in §§ 34-20B-11 to 34-20B-26; possession offence at SDCL § 22-42-5) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (sdlegislature.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on South Dakota's schedules or in a South Dakota-specific ban as of September 2026. That is the position in most states.

Human growth hormone

South Dakota's Schedule III lists a few named drugs and the anabolic steroids defined in § 34-20B-4.1 (80 named steroids); neither section mentions human growth hormone, somatropin or chorionic gonadotropin, so HGH is governed only by federal law. (SDCL § 34-20B-22(3) and § 34-20B-4.1) (sdlegislature.gov)

Compounded semaglutide and tirzepatide

2024-01. The Board of Pharmacy's January 2024 newsletter told licensees that 503A and 503B pharmacies may compound shortage-list GLP-1s only if the active ingredient is not a salt or other form of the drug (semaglutide may only be compounded with semaglutide base), noted that most spas and wellness centres dispense non-FDA-approved compounded product, reported one South Dakota adverse event from a tenfold dosing error, and flagged counterfeit semaglutide reports. (doh.sd.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No South Dakota medical board guidance specific to peptide therapy was located. A South Dakota prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in South Dakota

South Dakota has no offence for possessing an unscheduled research peptide; SDCL § 22-42-5 makes knowing possession of a controlled substance without a valid prescription a felony, which reaches anabolic steroids but not peptides such as BPC-157 or semaglutide. (sdlegislature.gov)

Ordering from a vendor in another state. Almost every research-peptide order into South Dakota is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. SDCL § 34-52-3 requires a proper provider-patient relationship via telehealth, with identity verification, consent, a diagnosis through acceptable medical practice including history and examination, and follow-up; § 34-52-5 requires an appropriate face-to-face examination using real-time audio and visual technology before diagnosis and treatment whenever an in-person encounter would otherwise be required. There is no in-person visit requirement for non-controlled drugs such as semaglutide, but a questionnaire-only model would not meet the statute. (sdlegislature.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a South Dakota law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in South Dakota

The Bureau found no South Dakota-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. South Dakota did not sign the February 2025 multistate letter, and no state attorney general or board enforcement action on peptides or compounded GLP-1s was found.

Frequently asked questions

Is BPC-157 legal in South Dakota?

South Dakota has not scheduled BPC-157, so possessing it is not a South Dakota offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in South Dakota?

Yes. SDCL § 34-52-3 requires a proper provider-patient relationship via telehealth, with identity verification, consent, a diagnosis through acceptable medical practice including history and examination, and follow-up; § 34-52-5 requires an appropriate face-to-face examination using real-time audio and visual technology before diagnosis and treatment whenever an in-person encounter would otherwise be required. There is no in-person visit requirement for non-controlled drugs such as semaglutide, but a questionnaire-only model would not meet the statute. The South Dakota Board of Pharmacy position on compounded versions: The Board of Pharmacy's January 2024 newsletter told licensees that 503A and 503B pharmacies may compound shortage-list GLP-1s only if the active ingredient is not a salt or other form of the drug (semaglutide may only be compounded with semaglutide base), noted that most spas and wellness centres dispense non-FDA-approved compounded product, reported one South Dakota adverse event from a tenfold dosing error, and flagged counterfeit semaglutide reports.

Is HGH legal in South Dakota?

Only with a valid prescription for an approved use. South Dakota does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every South Dakota fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.